Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Twist Bioscience
Adding the Biology Wet Lab to AI Training Loops
Skip to main content Article Algorithms propose designs in seconds, but a bench test confirms whether a sequence folds and functions. Brought to you byTwist Bioscience AI models can rapidly suggest the right genome edit or protein design. But an algorithm trained on digital datasets alone predicts how a sequence scores, rather than how it behaves. Candidates at the top of a model's list can misfold, aggregate, or express poorly once they reach a living cell.
Rethinking Codon Optimization for Recombinant Protein Expression
Skip to main content Whitepaper Explore how full-sequence context can shape optimization strategies and protein yield. Brought to you byTwist Bioscience Synonymous codons may encode the same amino acid, but host cells do not treat them as interchangeable. Codon preferences vary across species, so a sequence optimized for one organism can express poorly in another. How this optimization is performed is central to maximizing protein yield.
How Enzyme Engineering Improves NGS Library Preparation
Next-generation sequencing (NGS) workflows depend on enzymes at every stage, yet enzyme performance is often overlooked during workflow development and execution. From DNA fragmentation and adaptor ligation to target amplification, enzyme fidelity, efficiency, and robustness can significantly influence data quality, workflow speed, and confidence in experimental results. Emily M. LeProust, PhD Chief Executive Officer and Co-Founder Twist Bioscience In this Innovation Spotlight, Emily M.
Accelerating AI-Guided Antibody Discovery in Under Five Weeks
Skip to main content Webinar Explore an integrated workflow that combines AI-guided antibody design with automated biophysical characterization to accelerate antibody discovery from design to experimental validation in under five weeks. This webinar, brought to you by Twist Bioscience, will be hosted live and available on-demand. Tuesday, August 18, 2026 11:00 AM - 12:00 PM ET AI-guided approaches are reshaping antibody discovery by accelerating candidate design and optimization.
The Power of Complex Gene Synthesis
The gene synthesis landscape is continuously evolving in pursuit of perfection, with innovations often aimed at improving the speed, cost, and fidelity of oligonucleotide synthesis. More broadly, there is intense interest in developing RNA and cell therapeutics, as well as an ongoing inflection point in the advent of artificial intelligence (AI). As a result, there is an increasing need for reliable complex gene synthesis. Emily M.
TrueAmp Library Preparation Kit: Precise Prep for Your Target Enrichment Workflow
Skip to main content Product Built for More: Uniform Coverage, Higher Yields, and Confident Variant Characterization. The Twist TrueAmp Library Preparation Kit delivers consistent, high-quality libraries for NGS target enrichment workflows including challenging low-input, FFPE, and cfDNA samples.
Developing a standard definition for sequences of concern
Abstract Readily available nucleic acid synthesis is both critical for the bioeconomy and an increasingly pressing security concern due to the potential for accidental or deliberate misuse. While biosecurity experts broadly agree that nucleic acid providers should screen orders for potential “sequences of concern,” there has previously been no agreed standard for how to define and recognize such sequences.
Teaching AI to Invent Enzymes Nature Never Imagined
Skip to main content Webinar In this webinar, Chenghao Liu and Jarrid Rector-Brooks discuss multimodal protein co-design approaches for engineering enzymes with novel catalytic activity. This webinar, brought to you by Twist Bioscience, will be hosted live and available on-demand. Tuesday, June 30th, 2026 11:00 AM - 12:30 PM ET Evolution is an extraordinary engine for enzymatic diversity, yet the chemistry it has explored remains a narrow slice of what DNA can encode.
Beyond sequence similarity: toward function-based screening of nucleic acid synthesis
Abstract Synthetic nucleic acids are a key input to modern biotechnology, yet they represent dual-use materials that require robust screening to mitigate biosecurity risks. The prevailing screening paradigm, which identifies sequences of concern (SoCs) through sequence similarity to controlled pathogens and toxins, may not fully capture risks posed by AI tools that can decouple biomolecular function from reliance on known sequences.
Validation and Analysis of 12,000 AI-Driven CAR T Designs in the Bits to Binders Competition
Webinar Examine how large-scale screening of AI-designed binders informs CAR T-cell engineering and functional validation. This webinar, brought to you by Twist Bioscience, will be hosted live and available on-demand. Thursday, June 11th, 2026 11:00 AM - 12:00 PM ET Chimeric antigen receptor (CAR) T-cell therapy results in high rates of remission in patients with blood cancers and can result in durable, lasting cures.
Exploring a Cutting-Edge RNA Exome for Smarter Enrichment
Article Targeted sequencing can yield better results than whole transcriptome sequencing for a fraction of the cost. Whole transcriptome sequencing has yielded considerable benefits, but it may not provide the necessary depth for all applications. Targeted sequencing can provide better, more enriched results despite having fewer total reads. This, in turn, results in a lower overall cost while finding more genes and critical fusions.
Exploring a Lab-in-the-Loop System for Antibody Design
Article Discover how the latest approach to linear DNA expression workflows can streamline antibody design processes. Scientists engaged in therapeutic antibody development research face challenges balancing the competing properties of antibodies and the time-consuming iterative process of searching for ideal candidates. A new approach, termed Lab-in-the-Loop, uses machine learning, prediction, validation, and retraining to identify ideal antibody designs quickly and efficiently.
Building the Future of AI-Driven Nanobody and Antibody Design
Webinar In this webinar, Charlotte Deane will explore how artificial intelligence and computational biology are transforming nanobody and antibody therapeutic design. This webinar, brought to you by Twist Bioscience, will be hosted live and available on-demand. Tuesday, May 26, 2026 11:00 AM - 12:00 PM ET Developing new therapeutics remains a costly and time-intensive process, often requiring significant investment and years of research.
Using Site-Saturation Variant Libraries to Understand Viral Evolution
Article Discover how scientists bridge the gap between genomic detection and functional assessment to remain a step ahead of viral evolution. Viruses evolve rapidly and scientists encounter challenges staying ahead of new variants. Site-saturation mutagenesis allows researchers to create viral gene libraries that help them anticipate potential mutations and assess their functional impact before a virus mutates.
Twist Bioscience at Barclays Conference: Strategic Growth and Innovation
On Tuesday, 10 March 2026, Twist Bioscience (NASDAQ:TWST) shared its strategic vision at the Barclays 28th Annual Global Healthcare Conference. The company highlighted its focus on AI-driven drug discovery and NGS capabilities, showing robust growth despite a temporary setback with a key customer. The discussion underscored both opportunities and challenges in its path toward breakeven and market expansion.
DNA and Protein Tools for AI-Driven Biologics Design
Infographic High-quality DNA and protein datasets empower artificial intelligence (AI) models to accelerate biologics discovery, refinement, and development. Scientists are increasingly applying artificial intelligence (AI) to biologics discovery, including de novo protein design. However, complex sequence-function relationships and the need for high-quality, purpose-built datasets can limit the reliability of AI predictions.
Twist Bioscience and Element launch new fast sequencing workflow
SOUTH SAN FRANCISCO & SAN DIEGO - Twist Bioscience Corporation (NASDAQ:TWST) and Element Biosciences have introduced a new end-to-end sequencing solution that allows researchers to process samples in as little as five hours, according to a press release issued Monday.
Twist Bioscience at Baird Conference: Strategic Growth and Challenges
On Tuesday, 09 September 2025, Twist Bioscience (NASDAQ:TWST) presented at the Baird Global Healthcare Conference 2025, offering a strategic overview of its financial performance and future goals. The company highlighted its revenue growth and gross margin improvements but also acknowledged challenges in customer acquisition and market funding uncertainties. Key Takeaways Twist Bioscience aims for adjusted EBITDA breakeven by fiscal year 2026.
The Holy Grail Hunt in De Novo Antibody Design
Article Using AI and Multiplexed Gene Fragments, researchers developed a novel design approach to encode thousands of single-domain antibodies without compromising sequence integrity. Monoclonal antibodies (mAbs) have become a prominent therapeutic modality due to their binding specificity and ability to engage a diverse range of targets. However, isolating mAbs remains a laborious process, traditionally requiring animal immunization or vast library screens of randomly generated variants.
Detecting Minimal Residual Disease Through Sequencing
Article Next-generation sequencing powered liquid biopsies can be an effective way to detect residual cancer after primary treatment. Minimal residual disease (MRD) is a term referring to the small populations of cancer cells that may remain in the body following primary treatment. Early and accurate MRD detection is important for predicting relapse risk, guiding treatment, and improving patient outcomes.
New Horizons in High-Throughput Screening - A Special Podcast Series
Synthetic technologies allow scientists to venture into uncharted waters, asking unique research questions and finding previously unattainable solutions to some of life’s biggest mysteries. From gene editing to protein engineering, synthesized DNA libraries enable researchers to grasp once unreachable high-throughput screening applications and dismantle barriers between experimental ideation and execution.
Twist Bioscience and bitBiome launch enzyme screening kit
SOUTH SAN FRANCISCO, Calif. & TOKYO - Twist Bioscience (NASDAQ:) Corporation (NASDAQ:TWST) and bitBiome Inc. have announced the release of a new Transaminase Enzyme Screening Kit, a collection of forty-eight diverse transaminase enzymes. This product aims to support the pharmaceutical industry by providing a more environmentally friendly alternative for synthesizing chiral amines, which are key components in drug manufacturing.
Cell and gene therapy product reviews
News The tech used by cell and gene therapy scientists Editorial Article: The tech used by cell and gene therapy scientists Find out which lab products scientists are using to advance the field and what their experiences have been 12 Jan 2024 Insights into lab equipment and services other scientists are using can be invaluable. The independent reviews on SelectScience® are there to help guide and support your own research and give you a platform to share your expert opinions.
Cell and gene therapy product reviews
News The tech used by cell and gene therapy scientists Editorial Article: The tech used by cell and gene therapy scientists Find out which lab products scientists are using to advance the field and what their experiences have been 12 Jan 2024 Insights into lab equipment and services other scientists are using can be invaluable. The independent reviews on SelectScience® are there to help guide and support your own research and give you a platform to share your expert opinions.
Synthetic Libraries: Where Science Meets Impact
Variant libraries are powerful tools for investigating genetic variations and advancing various fields of research, including genetics, medicine, biotechnology, and drug discovery.
Update on Standards for Consuming DNA Data Storage Archives
DNA lacks many key attributes found in other traditional storage media types including locality and addressability. The Rosetta Stone workgroup is aiming to solve the issue of enabling archive readers to understand key metadata about the archive and position them to be able to consume its contents. This session will provide an overview of where the Rosetta Stone workgroup is in the process of creating a recommended approach for this issue.
A comparison of the binding sites of antibodies and single-domain antibodies
Gemma L. Gordon1, Henriette L. Capel1, Bora Guloglu1, Eve Richardson1, Ryan L. Stafford2 and Charlotte M. Deane1* 1Oxford Protein Informatics Group, Department of Statistics, University of Oxford, Oxford, United Kingdom 2Twist Bioscience, South San Francisco, CA, United States Antibodies are the largest class of biotherapeutics. However, in recent years, single-domain antibodies have gained traction due to their smaller size and comparable binding affinity.
Optimization of a glucagon-like peptide 1 receptor antagonist antibody for treatment of hyperinsulinism
Citation Sean M. Peterson, Christine A. Juliana, Cameron F. Hu, Jinghua Chai, Carson Holliday, Kara Y. Chan, Ana G. Lujan Hernandez, Zoe Challocombe, Linya Wang, Zhen Han, Nikhil Haas, Ryan Stafford, Fumiko Axelrod, Tom Z. Yuan, Diva D. De Leόn, Aaron K. Sato; Optimization of a glucagon-like peptide 1 receptor antagonist antibody for treatment of hyperinsulinism. Diabetes 2023; db221039. https://doi.org/10.2337/db22-1039 Download citation file:
A comparison of the binding sites of antibodies and single-domain antibodies
Gemma L. Gordon1*, Henriette L. Capel1, Bora Guloglu1, Eve Richardson1, Ryan L. Stafford2 and Charlotte M. Deane1* 1University of Oxford, United Kingdom 2Twist Bioscience, United States The final, formatted version of the article will be published soon. Receive an email when it is updated Antibodies are the largest class of biotherapeutics.
TWIST BIOSCIENCE CORP : Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits (form 8-K) | MarketScreener
Item 2.02Results of Operations and Financial Condition. On May 5, 2023, Twist Bioscience Corporation (the "Company" or "Twist Bioscience") issued a press release announcing its financial results for the quarter ended March 31, 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The Growth of NGS in Agriculture
DNA sequencing is a technology that's known the world over for its impact in molecular research and health fields. However, in recent years, the decreasing cost of sequencing has fueled a growing interest in applying this technology beyond its traditional sectors. One such application is in the agricultural space, where next-generation sequencing (NGS) is modernizing an ancient form of crop production.
BusinessWire - Twist Bioscience (TWST) CLASS ACTION ANNOUNCEMENT: Kessler Topaz Meltzer Check, LLP Has Filed A Securities Fraud Class Action Lawsuit Against Twist Bioscience Corporation | ResearchPool
The law firm of informs investors that the firm has filed a against Twist Bioscience Corporation (“Twist”) () on behalf of investors who purchased or acquired Twist common stock between December 13, 2019 and November 14, 2022, inclusive (the “Class Period”). This action, captioned Peters v. Twist Bioscience Corporation, et al., Case No. 3:22-cv-08168, was filed in the United States District Court for the Northern District of California and is assigned to the Honorable Edward J. Davila.
This Year’s Top Moments In Biotech
In many ways, synthetic biology is the unseen tide that raises all ships. The tools and techniques that come from this fast-growing field help to drive advancements in genetics, they open doors to novel therapeutic modalities, and they make it possible to engineer better, more sustainable sources of food.
Drug discovery solutions for your lab
We’ve highlighted lab product reviews of drug discovery lab solutions that could benefit your workflows and research Choosing the right lab equipment can be a complex decision. That’s why SelectScience® lab product reviews can be a valuable tool, enabling you to make an informed choice and hear what other scientists have working in drug discovery have to say. We’ve pulled together some reviews on drug discovery lab solutions, that could benefit your laboratory’s workflows.
Examining Language on Indigenous Peoples’ Day
Indigenous Peoples’ Day is a time when we rethink history and acknowledge the contributions of indigenous people to our country and society. This Indigenous Peoples’ Day we’re reflecting on the language rooted in or appropriated from Indigenous cultures that we use in our daily interactions. Examining Language Some of the terms and phrases that we use in our day-to-day interactions are appropriated from Indigenous cultures.
Synthetic DNA’s Critical Role in Infectious Disease Research
On September 22, 2017, an 11-year-old boy was admitted to the Niger Delta University Teaching Hospital in Nigeria. For more than a week, the boy had been lethargic and feverish with large lesions dotting his body. Though it hadn’t been reported in Nigeria for nearly 40 years, the boy appeared to be infected with the monkeypox virus1.
Join Nextech AR at the Wall Street Reporter Livestream Event on April 5, 2022
TORONTO–(BUSINESS WIRE)–$NEXCF #3D—Nextech AR Solutions Corp. (“Nextech” or the “Company”) (OTCQB: NEXCF) (NEO: NTAR) (CSE: NTAR) (FSE: N29), a Metaverse Company and leading provider of augmented reality (“AR”) experience technologies and services announces that Nextech AR Solutions CEO Evan Gappelberg will present at the “NEXT SUPER STOCK Live!” event hosted by the Wall Street Reporter.
TouchBistro Launches Marketing and CRM Platform to Help Restaurants Drive Repeat Business
TouchBistro Marketing is a POS-integrated platform for automating customized promotions TORONTO & NEW YORK–(BUSINESS WIRE)–#CRM—TouchBistro today announced the launch of TouchBistro Marketing, a comprehensive marketing and customer relationship management (CRM) platform that connects restaurants with their guests and drives repeat visits by helping operators automate custom marketing campaigns and promotions.
The interplay of additivity, dominance, and epistasis on fitness in a diploid yeast cross - Nature Communications
Abstract In diploid species, genetic loci can show additive, dominance, and epistatic effects. To characterize the contributions of these different types of genetic effects to heritable traits, we use a double barcoding system to generate and phenotype a panel of ~200,000 diploid yeast strains that can be partitioned into hundreds of interrelated families. This experiment enables the detection of thousands of epistatic loci, many whose effects vary across families.
High-throughput Spatial Genomics| Twist Bioscience
Rather than a neat, linear sequence of As, Gs, Cs, and Ts, our genome better resembles a bowl of spaghetti: a mess of intermingling loops of DNA strewn about. Or at least that’s the way we viewed it before the advent of fluorescence in situ hybridization (FISH), a method that involves labeling genomic DNA with fluorescently tagged oligos. Just as cells are not simply bags of enzymes, nuclei are not bowls of chromosomal spaghetti.
AKIRIN2 controls the nuclear import of proteasomes in vertebrates - Nature
Abstract Protein expression and turnover are controlled through a complex interplay of transcriptional, post-transcriptional and post-translational mechanisms to enable spatial and temporal regulation of cellular processes.
Methylation sequencing of cfDNA
In the milieu of rushing blood, plasma, and cells, small wayward bits of DNA are easy to overlook. But stored within these scraps of genetic material, known as cell-free DNA (cfDNA), is information offering the earliest glimpses of cancer development. Being able to detect and understand these signals could dramatically improve our ability to detect and treat cancer before the disease has developed.
Antibody Development: Collaboration and Partnerships
Twist Biopharma is a division of Twist Bioscience with a mission to solve some of the world’s most intractable health challenges through next-generation drug development. In the three short years since Twist Biopharma’s launch, it’s formed more than 20 partnerships that have now led to 25 active programs that range in application from oncology to veterinary medicine. And, there’s likely many more to come as the Twist Biopharma team continues to build out its services.
A Conversation with Emily Leproust
Request Username Can't sign in? Forgot your username? Enter your email address below and we will send you your username Email If the address matches an existing account you will receive an email with instructions to retrieve your username
Targeted RNA-seq expands the early cancer detection toolkit
RNA-seq is an essential research tool that holds exciting prospects for the early detection of cancer. However, in clinical samples highly abundant mRNA and rRNA sequences obscure rarer RNA subtypes that may hold the keys to early cancer detection, such as long non-coding RNA.
Invitae to Raise $400M in Proposed Public Offering
NEW YORK – Invitae announced after the close of the market Wednesday that it aims to raise $400 million through an underwritten public offering of nearly 7.2 million shares of its common stock based on an assumed price of $55.86 per share.
Interpace Bio Q3 Revenues Rise 6 Percent
NEW YORK – Interpace Biosciences reported Wednesday morning that its third quarter revenues rose 6 percent year over year. For the three months ended Sept. 30, 2020 the Parsippany, New Jersey-based firm had total revenues of $8.2 million compared to $7.7 million a year ago, beating analysts' average expectations of $7.6 million. Interpace also announced that it closed a $5 million bridge loan with existing equity investors Ampersand Capitol Partners and 1315 Capital Partners earlier this month.
Bio-Rad, United Biomedical Get FDA Emergency Use Authorizations for Coronavirus Tests
NEW YORK — The US Food and Drug Administration last week granted separate Emergency Use Authorizations for SARS-CoV-2 tests developed by Bio-Rad Laboratories and United Biomedical. The Bio-Rad Reliance SARS-CoV-2 RT-PCR Assay Kit is designed to detect the SARS-CoV-2 N gene in upper respiratory tract specimens including nasopharyngeal, oropharyngeal, nasal, anterior nasal, and midturbinate nasal swabs, as well as nasal aspirates and nasal washes.
Lucira Health Files for $115M IPO
NEW YORK — Lucira Health, a developer of an instrument-free, low-cost molecular diagnostics platform for infectious disease testing, filed for a $115 million initial public offering with the US Securities and Exchange Commission last week. In the filing, the Emeryville, California-based company said it intends to float an undisclosed number of shares on the Nasdaq at a yet-to-be-determined price under the ticker symbol LHDX.
Hamilton Storage, Harvard Spinout Rhinostics Partner for High-Throughput Sample Processing
You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Twist
Contact Twist, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack